Patents by Inventor Zhaoxiang BIAN

Zhaoxiang BIAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250082660
    Abstract: The present invention belongs to the field of medical technology and specifically relates to an active ingredient group for treating constipation. An active ingredient group for treating constipation, characterized in that the active ingredient group includes rhein, hesperetin, albiflorin, and magnolol. The key target combination of constipation includes RXRA, CYP1A1, CYP1A2 and PLA2G4. The active ingredient group for treating constipation provided in this application can effectively prevent and treat constipation by regulating bile acid secretion, steroid hormone biosynthesis, glycerophospholipid metabolism, and linoleic acid metabolism by establishing strong combination between the active ingredient group and the key target combination of constipation. This application also discloses the biomarkers for the diagnosis and treatment of constipation.
    Type: Application
    Filed: December 6, 2023
    Publication date: March 13, 2025
    Inventors: Zhaoxiang Bian, Lin Zhu, Jingchun Shi, Ka Wing Cheng, Yan Yan Lam, Ziwan Ning, Chengyuan Lin
  • Publication number: 20250082713
    Abstract: The present invention belongs to the field of medical technology and specifically relates to an active ingredient group for treating UC. An active ingredient group for treating UC, characterized in that it uses an active ingredient group to act on key target combination of UC, and prevents and treats UC by regulating tryptophan metabolism, glycerolphospholipid metabolism, and linoleic acid metabolism. The active ingredient group for treating UC provided in this application can effectively prevent and treat UC by regulating tryptophan metabolism, glycerolphospholipid metabolism and linoleic acid metabolism by establishing strong combination between the active ingredient group and the key target combination of UC. This application also discloses the biomarkers for the diagnosis and treatment of UC.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 13, 2025
    Inventors: Zhaoxiang Bian, Lin Zhu, Ka Wing Cheng, Hor Yue Tan, Jingchun Shi, Chunhua Huang, Chengyuan Lin
  • Publication number: 20240307361
    Abstract: Provided herein is a method of diagnosing irritable bowel syndrome in a subject involving determining the amount of at least one of Ruminococcus gnavus, phenethylamine, tryptamine and tyramine in a fecal sample obtained from the subject. Also provided is a method of treating irritable bowel syndrome in a subject in need thereof involving the administration of a therapeutically effective amount of a trace amine-associated receptor 1 inhibitor.
    Type: Application
    Filed: February 16, 2023
    Publication date: September 19, 2024
    Inventors: Zhaoxiang BIAN, Hoi Leong Xavier WONG, Lixiang ZHAI, Johnson Yiu-Nam LAU
  • Publication number: 20240295566
    Abstract: Provided herein is a method of diagnosing a metabolic disorder in a subject involving determining the amount of at least one of Ruminococcus gnavus, phenethylamine, and tryptamine in a fecal sample obtained from the subject. Also provided is a method of treating a metabolic disorder in a subject in need thereof involving the administration of a therapeutically effective amount of a trace amine-associated receptor 1 inhibitor.
    Type: Application
    Filed: February 16, 2023
    Publication date: September 5, 2024
    Inventors: Zhaoxiang BIAN, Hoi Leong Xavier WONG, Lixiang ZHAI, Johnson Yiu-Nam LAU, Chengyuan LIN, Haitao XIAO
  • Publication number: 20240269211
    Abstract: The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a green and healthy medicine composition for preventing and treating inflammatory bowel disease. The medicine composition comprises: 15-25 g of roots of Codonopsis pilosula (Franch.) Nannf., 5-15 g of Atractylodes macrocephala Koidz., 15-25 g of Poria cocos (Schw.) Wolf, 1-10 g of Cornus officinalis Sieb. et Zucc., 1-10 g of Coptis chinensis Franch., 1-10 g of Curcuma Longa L., 5-15 g of Paederia scandens (Lour.) Merr., 5-15 g of Bletilla striata (Thunb.) Reichb.f., and 1-10 g of Glycyrrhiza uralensis Fisch. The solution disclosed by the present application has significant beneficial effect on the prevention and treatment of inflammatory bowel disease, and the herbs used in the present application are widely used traditional Chinese medicine products with no or low toxic effect; therefore, the green and healthy medicine composition has green, healthy and safe technical advantages.
    Type: Application
    Filed: February 11, 2023
    Publication date: August 15, 2024
    Inventors: Zhaoxiang BIAN, Chengyuan LIN, Haitao XIAO, Lixiang ZHAI, Hor Yue TAN
  • Publication number: 20240148751
    Abstract: A method of treating a glucose-6-phosphate dehydrogenase deregulated disorder in a subject in need thereof, the method involving administering a therapeutically effective amount of oleanolic acid or a conjugate salt thereof or prodrug thereof to the subject. The glucose-6-phosphate dehydrogenase deregulated disorder can be BCL2 associated athanogene myofibrillar myopathy, amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, or Alzheimer disease.
    Type: Application
    Filed: October 13, 2022
    Publication date: May 9, 2024
    Inventors: Zhaoxiang BIAN, Tao HUNG, Ling ZHAO, Lidan ZHONG, Chengyuan LIN
  • Patent number: 11952358
    Abstract: Provided herein are compounds useful in the treatment of inflammatory diseases, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The compounds exhibit inhibitory effects on the expression and secretion of pro-inflammatory cytokines, such as IL-1?, IL-6 and TNF-?.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: April 9, 2024
    Assignee: Hong Kong Baptist University
    Inventors: Jun Wang, Zihao Wang, Qingjing Yang, Zhaoxiang Bian
  • Publication number: 20230381257
    Abstract: An herbal composition including Fructus Terminaliae Chebulae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Corydalis Yanhusuo, Herba Polygoni Chinensis, Rhizoma Atractylodis Macrocephalae, and Semen coicis Lachryrna-jobi useful for treating diseases, such as inflammatory bowel disease, by increasing regulatory T cells in a subject in need thereof, methods for preparing of use and preparation thereof.
    Type: Application
    Filed: May 23, 2023
    Publication date: November 30, 2023
    Inventors: Zhaoxiang BIAN, Ying WANG, YiTao WANG
  • Publication number: 20230159482
    Abstract: Provided herein are compounds useful in the treatment of inflammatory diseases, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The compounds exhibit inhibitory effects on the expression and secretion of pro-inflammatory cytokines, such as IL-1?, IL-6 and TNF-?.
    Type: Application
    Filed: November 16, 2022
    Publication date: May 25, 2023
    Inventors: Jun WANG, Zihao WANG, Qingjing YANG, Zhaoxiang BIAN
  • Publication number: 20210395309
    Abstract: Provided herein are Bradykinin-potentiating peptide chemotherapeutic drug conjugates useful as cancer therapeutics, pharmaceutical compositions comprising the same, and methods of preparation and use thereof.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 23, 2021
    Inventors: Zhaoxiang BIAN, Tao HUANG, Xuanming GUO, Chengyuan LIN
  • Patent number: 10973823
    Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 13, 2021
    Assignee: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Guoqing Chen, Ruihong Gong, Dajian Yang, Aiping Lyu
  • Publication number: 20190388424
    Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.
    Type: Application
    Filed: September 27, 2016
    Publication date: December 26, 2019
    Inventors: Zhaoxiang BIAN, Guoqing CHEN, Ruihong GONG, Dajian YANG, Aiping LYU
  • Patent number: 10376555
    Abstract: Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 13, 2019
    Assignee: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Tao Huang, Chengyuan Lin
  • Publication number: 20180289766
    Abstract: Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.
    Type: Application
    Filed: March 20, 2018
    Publication date: October 11, 2018
    Inventors: Zhaoxiang BIAN, Tao HUANG, Chengyuan LIN
  • Patent number: 10040740
    Abstract: The present invention relates to an atom economic procedure of preparing iodoalkanes by hydroiodination of alkenes. In particular the present method features the generation of anhydrous hydrogen iodide from atomic hydrogen and iodine in situ by using transition metal precursor and phosphine ligandcatalyst.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: August 7, 2018
    Assignees: Hong Kong Baptist University, Yunnan Minzu University
    Inventors: Zhaoxiang Bian, Baomin Fan, Chengyuan Lin, Yongyun Zhou, Jingchao Chen
  • Patent number: 9980906
    Abstract: The present invention provides a slow and controlled released liposomal gel composition for subcutaneous administration comprises insulin or exenatide as active ingredient for reduction of blood sugar level and method of preparation thereof. Said controlled released composition has high bioavailability and is demonstrated to be able to sustain release therapeutically effective concentration of drug over a period of time and without rapid release of drug after initial administration. Method of preparing the controlled released composition of the present invention comprises the following steps: mixing insulin or exenatide, lipid and aqueous dispersion medium together; then mixing with poloxamer (e.g. F127 or P123) and/or gelatin and hyaluronic acid (HA) or the like gel solution so as to form a protective layer on surface of every lipid micro vesicles or nano-vesicles for use in intramuscular, abdominal and subcutaneous administration.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 29, 2018
    Assignee: Hong Kong Baptist University
    Inventors: Zhijun Yang, Aiping Lu, Zhaoxiang Bian, Xiaoyu Chen, Blenda Chi Kwan Wong
  • Patent number: 9868716
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity,
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 16, 2018
    Assignees: HONG KONG BAPTIST UNIVERSITY, SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE
    Inventors: Hongxi Xu, Yue Lv, Wenwei Fu, Kaixian Chen, Zhaoxiang Bian, Shilin Chen, Dajian Yang, Aiping Lu, Sun Chi Albert Chan
  • Patent number: 9783519
    Abstract: This invention relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds. More particularly, it relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds comprising phenylacetophenone derivatives using oxabenzonorbornadienes with terminal alkynes.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: October 10, 2017
    Assignees: HONG KONG BAPTIST UNIVERSITY, YUNNAN MINZU UNIVERSITY
    Inventors: Zhaoxiang Bian, Chengyuan Lin, Huaixue Mu, Baomin Fan, Yongyun Zhou, Jingchao Chen, Aiping Lu, Albert Sun-Chi Chan
  • Patent number: 9775857
    Abstract: The present invention relates to chemical constituents of the hydro-alcoholic extract of root of Lasia spinosa (L.) Thwait. More particularly, it relates to the bioactive chemical composition of Lasia spinosa (L.) Thwait and its anticancer effect. The present invention has application in the treatment of human esophageal carcinoma.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: October 3, 2017
    Assignee: HONG KONG BAPTIST UNIVERSITY
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20170204022
    Abstract: The present invention relates to an atom economic procedure of preparing iodoalkanes by hydroiodination of alkenes. In particular the present method features the generation of anhydrous hydrogen iodide from atomic hydrogen and iodine in situ by using transition metal precursor and phosphine ligandcatalyst.
    Type: Application
    Filed: January 13, 2017
    Publication date: July 20, 2017
    Inventors: Zhaoxiang BIAN, Baomin FAN, Chengyuan LIN, Yongyun ZHOU, Jingchao CHEN